EX-10.8.3



 Exhibit 10.8.3 
 [*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

 AMENDMENT #3 TO THE COLLABORATION AND OPTION AGREEMENT 

THIS AMENDMENT #3 TO THE COLLABORATION AND
OPTION AGREEMENT (together with any appendices attached hereto, this “Amendment #3”) is made and entered into as of June 16, 2011 (the “Amendment #3 Effective Date”), by and
between GlobeImmune, Inc., a Delaware corporation located at 1450 Infinite Drive, Louisville, Colorado 80027, United States of America (“GlobeImmune”), and Celgene Corporation, a Delaware corporation located at 86 Morris
Avenue, Summit, New Jersey 07901, United States of America (“Celgene”). GlobeImmune and Celgene are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

 RECITALS 
 WHEREAS, GlobeImmune and Celgene are parties to the Collaboration and Option Agreement, effective as of May 14, 2009, as amended on November 6, 2009 and February 9, 2010 (the
“Agreement”), which sets forth certain rights and obligations of both Parties relating to a certain collaboration, research and development activities for certain drug candidates and future drug programs; 

WHEREAS, Celgene and GlobeImmune desire to revise and amend the Agreement to add the Collaboration Compound known as GI-6300 as a Drug Candidate under the Agreement and to remove the Collaboration Compound known as GI-10000 as a Drug Candidate under the Agreement; and 

WHEREAS, capitalized terms used herein but not defined herein shall have the definitions set forth in the Agreement. 

AGREEMENT 

NOW, THEREFORE, GlobeImmune and Celgene agree as follows: 
 1. Section 1.34 of the Agreement shall be deleted in its entirety and replaced with the following: 
 “1.34 “Drug Candidate” means GI-4000, GI-6200, GI-3000, or GI-6300.” 
 2. Section 1.53 of the Agreement shall be deleted in its entirety and
replaced with the following: 
 “1.53 “GI-6300” has the meaning set
forth on Exhibit 1.34.” 
 3. Section 3.2.1 of the Agreement shall be deleted in its entirety and replaced with the
following: 
 “3.2.1 Commencement of GlobeImmune Development Activities. GlobeImmune represents and warrants that


  
 1. 










 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 
GlobeImmune, as of the Effective Date, has initiated (a) research Execution Copy activities for the Program containing GI-3000 and (b) research
and development activities for the Programs containing GI-4000 and GI-6200. GlobeImmune represents and warrants that GlobeImmune, as of the Amendment #3 Effective
Date, has initiated research activities for the Program containing GI-6300. After the Effective Date, GlobeImmune shall provide written notice to Celgene promptly after commencing any additional
Development efforts for any Collaboration Compound. After exercise of a Celgene Program Option, upon the request of Celgene and agreement of GlobeImmune, in GlobeImmune’s sole discretion, GlobeImmune may conduct Development activities with
respect to the applicable Celgene Development Compound.” 
 4. Section 6.2.3 of the Agreement shall be deleted in its
entirety and replaced with the following: 
 “6.2.3 Research and Development Milestones for Drug Candidates Other than
the GI-4000 Program. 
 (a) GI-6200 and GI-3000. If Celgene exercises the Celgene Program Option with respect to a Program containing any of GI-6200 or GI-3000, in
consideration of the research and Development work performed by GlobeImmune under this Agreement for such GI-6200 or GI-3000 Program, as applicable, Celgene will pay,
within thirty (30) days following the date of achievement of each milestone below (or, if achievement of such milestone is within the control of GlobeImmune, within thirty (30) days following Celgene’s receipt of notice of the
achievement of such milestone), to GlobeImmune the following milestone payments once each upon the achievement of the designated milestone events per each Program. Each payment will be made once regardless of how many Collaboration Compounds in the
Program may achieve each milestone event. If any milestone event relating to development (excluding Regulatory Approval milestones) is achieved, all previously listed development milestone events, if not already achieved, shall be considered to be
simultaneously achieved. 
  

					
	 Milestone Event
	  	Payment	 
	 [*]
	  	 	[*	] 
	 [*]
	  	 	[*	] 
	 [*]
	  	 	[*	] 
	 [*]
	  	 	[*	] 
	 [*]
	  	 	[*	] 
	 Total Per Drug Candidate Program
	  	$	85,000,000	  


  
 2. 










 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 (b) GI-6300. If Celgene exercises the
Celgene Program Option with respect to the Program containing GI-6300, in consideration of the research and Development work performed by GlobeImmune under this Agreement for the Program for GI-6300, Celgene will pay, within thirty (30) days following the date of achievement of each milestone below (or, if achievement of such milestone is within the control of GlobeImmune, within thirty
(30) days following Celgene’s receipt of notice of the achievement of such milestone), to GlobeImmune the following milestone payments once each upon the achievement of the designated milestone events per the Program for GI-6300. Each payment will be made once regardless of how many Collaboration Compounds in the GI-6300 Program may achieve each milestone event. If any milestone event relating
to development (excluding Regulatory Approval milestones) is achieved, all previously listed development milestone events, if not already achieved, shall be considered to be simultaneously achieved. 

 

					
	 Milestone Event
	  	Payment	 
	 Completion of first Phase 1 Trial and exercise of the Celgene Program Option for the GI-6300 Program in accordance with Section
4.1.1
	  	 	$8,000,000	  
	 [*]
	  	 	[*	] 
	 [*]
	  	 	[*	] 
	 [*]
	  	 	[*	] 
	 [*]
	  	 	[*	] 
	 [*]
	  	 	[*	] 
	 [*]
	  	 	[*	] 
	 Total for GI-6300 Program
	  	$	101,000,000	  


  
 3. 










 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 5. Exhibit 1.34 of the Agreement shall be deleted in its entirety and replaced with the
Exhibit 1.34 set forth in Appendix A attached hereto. 
 6. Exhibit 1.68 of the Agreement shall be deleted in its entirety and
replaced with the Exhibit 1.68 set forth in Appendix B attached hereto. 
 7. Pursuant to Section 8.2.8 of the Agreement,
Exhibit 1.57 of the Agreement shall be deleted in its entirety and replaced with the Exhibit 1.57 set forth in Appendix C attached hereto. 
 8. Pursuant to Section 8.2.8 of the Agreement, Exhibit 1.91 of the Agreement shall be deleted in its entirety and replaced with the Exhibit 1.91 set forth in Appendix D attached hereto. 

9. Schedule A of the Agreement shall be deleted in its entirety and replaced with the Schedule A set forth in Appendix E attached hereto.

 10. Celgene hereby acknowledges and agrees that the Collaboration Compound known as
GI-10000 shall not be deemed a Drug Candidate under the Agreement. GlobeImmune hereby acknowledges and agrees that (a) the Collaboration Compound known as GI-10000
may become a Future Program Compound under the Agreement (if the terms and conditions thereof of the Agreement are met) and remains subject to the terms and conditions of the Agreement, including the obligations of Section 5.6 of the Agreement;
and (b) this Amendment #3 shall not be deemed a termination of the Program containing GI-10000 under the Agreement. 
 11. Except as otherwise amended by this Amendment #3, the Agreement shall remain in full force and effect as presently written, and the rights, duties, liabilities and obligations of the Parties, as
presently constituted, will continue in full effect. 
 12. In the event of any conflict between the terms of the Agreement and
this Amendment #3, the terms of this Amendment #3 shall govern but only to the extent necessary to accomplish its purpose. 

13. This Amendment #3, together with the Agreement, constitutes the entire agreement between the Parties with respect to the subject
matter contained therein and herein, supersedes and replaces any and all prior and contemporaneous understandings, arrangements and agreements, whether oral or written, with respect to such subject matter. 

14. This Amendment #3 may be executed in counterparts, each of which shall be deemed an original, but both of which together shall
constitute one and the same instrument. Signatures to this Amendment #3 transmitted by facsimile, by email in “portable document format” (“.pdf”), or by any other electronic means intended to preserve the original graphic and
pictorial appearance of this Amendment #3 shall have the same effect as physical delivery of the paper document bearing original signature. 

  
 4. 










 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 [Signature Page Follows] 

  
 5. 










 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 IN WITNESS WHEREOF,
GlobeImmune and Celgene have executed this Amendment #3 by their duly authorized representatives as of the Amendment #3 Effective Date. 
  

									
	GLOBEIMMUNE, INC.	 		 	CELGENE CORPORATION
					
	By:	 	 /s/ Timothy C. Rodell, M.D.
	 		 	By:	 	 /s/ Robert J. Hugin

					
	Name:	 	Timothy C. Rodell, M.D.	 		 	Name:	 	Robert J. Hugin
					
	Title:	 	President and CEO	 		 	Title:	 	Chairman and CEO

 [Signature Page to Amendment #3 to Collaboration and Option Agreement] 

  
 6. 










 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 Appendix A 








 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 Exhibit 1.34 

Drug Candidates 
 GI-4000 means the series of Tarmogen products that express mutated Ras and/or one or more peptides thereof. GI-4014, GI4015, GI4016 and GI4020 are part of the GI-4000 series and are the subject of IND No. [*]. 
 GI-6200 means
the series of Tarmogen products that solely express human carcinoembryonic antigen (CEA). GI-6207 is part of the GI-6200 series and means the single Tarmogen product
that is the subject of IND No. [*], and that solely expresses human CEA having a N610D mutation. 

GI-3000 means the series of Tarmogen products that solely express human epidermal growth factor receptor (EGFR). GI-3010 is part of the GI-3000 series and means the single Tarmogen product that is the subject of [*], and that solely expresses human EGFR lacking the secretory signal
sequence and the transmembrane domain. 
 GI-6300 means the series of Tarmogen products that express
brachyury. GI-6301 is part of the GI-6300 series and means the single Tarmogen product that may become the subject of [*] and that expresses a human brachyury protein.









 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 Appendix B 








 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 Exhibit 1.68 

Initial Development Plan 

GlobeImmune will be responsible for conducting all Development activities through Completion of the endpoint set forth below for each of the following
Drug Candidates: 
 Activities, endpoints and costs: 
 1) Drug Candidate - GI-4000 
 [*] 
 2) Drug Candidate - GI-6300 
 [*] 
 3) Drug Candidate - GI-6200 
 [*] 
 4) Drug Candidate - GI-3000 
 [*] 








 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 Description of Clinical Trials referenced above: 

 

					
	 Drug Candidate
	  	Clinical Trial	 	Status
	 GI-4000
	  	[*]	 	
			
	 GI-6200
	  	[*]	 	
			
	 GI-6300
	  	[*]	 	









 [*] = Certain confidential information contained in this document, marked by brackets, is filed
with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 Appendix C 








 [*] = Certain confidential information contained in this document, marked by brackets, is filed
with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 Exhibit 1.57 

GlobeImmune Licensed Patent(s) 
 Patents and Patent Applications Owned or Co-Owned by GlobeImmune: 
  

									
	 GI Docket No.
	 	 Application No.

Filing Date
	 	 Country
	 	 Status
	 	 Owners or

Co-Owners



[* 5 pages of text omitted] 








 [*] = Certain confidential information contained in this document, marked by brackets, is filed
with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 Patents and Patent Applications Licensed from The Regents of the University of Colorado:

  

							
	 GI Docket No.
	 	 Application No.

Filing Date
	 	 Country
	 	 Status



[*] 
 Patents Licensed from Washington
Research Foundation: 
  

					
	 Application No.
 Filing Date
	 	 Country
	 	 Status



[*] 
 Patents Licensed from National
Institutes of Health: 
  

					
	 Application No.
 Filing Date
	 	 Country
	 	 Status



[*] 








 [*] = Certain confidential information contained in this document, marked by brackets, is filed
with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 Appendix D 








 [*] = Certain confidential information contained in this document, marked by brackets, is filed
with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 Exhibit 1.91 

Platform Patents 

Patents and Patent Applications Owned or Co-owned by GlobeImmune: 

 

									
	 GI Docket No.
	 	 Application No.

Filing Date
	 	 Country
	 	 Status
	 	 Owners or

Co-Owners



[*2 pages of text omitted] 
 Patents
and Patent Applications Licensed from The Regents of the University of Colorado: 
  

							
	 GI Docket No.
	 	 Application No.

Filing Date
	 	 Country
	 	 Status



[*] 
 Patents Licensed from Washington
Research Foundation: 
  

					
	 Application No.
 Filing Date
	 	 Country
	 	 Status



[*] 








 [*] = Certain confidential information contained in this document, marked by brackets, is filed
with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 Appendix E 








 [*] = Certain confidential information contained in this document, marked by brackets, is filed
with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 Schedule A 

Third Party Agreement(s) 

Agreements as of the Effective Date 

“Cooperative Research and Development Agreement (CRADA) for Intramural- PHS Clinical Research” between GlobeImmune, Inc. and The U.S.
Department of Health and Human Services, as represented by National Cancer Institute, an Institute, Center, or Division of the NIH, effective May 8, 2008. 
 “Materials Transfer Agreement” between GlobeImmune, Inc. and The Regents of the University of Colorado (James DeGregori, Ph.D., principal investigator), effective February 18, 2009.

 “Materials Transfer Agreement” between GlobeImmune, Inc. and The Regents of the University of Colorado (James DeGregori,
Ph.D., principal investigator), effective March 5, 2009. 
 [ * ] 
 Agreements Following the Effective Date 
 “Clinical Trial Agreement”
between GlobeImmune, Inc. and Georgetown University, effective December 1, 2009. 
 [ * ]